nelfinavir has been researched along with amprenavir in 117 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (7.69) | 18.2507 |
| 2000's | 81 (69.23) | 29.6817 |
| 2010's | 23 (19.66) | 24.3611 |
| 2020's | 4 (3.42) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Almond, MR; Bock, WJ; Cleary, DG; Furfine, ES; Hazen, RJ; Kazmierski, WM; Salituro, FG; Spaltenstein, A; Tung, RD; Wright, LL | 1 |
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Furfine, ES; Hanlon, MH; Hazen, RJ; Miller, JF; Ray, JA; Robinson, L; Samano, V; Spaltenstein, A | 1 |
| Danielson, UH; Shuman, CF; Vrang, L | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT | 1 |
| Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A | 1 |
| Garg, R; Patel, D | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Brenner, BG; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Diederich, WE; Kuhnert, M; Steuber, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Boden, D; Markowitz, M | 1 |
| Berger, J; Li, Z; MacNaul, K; Moller, DE; Szalkowski, D; Zhang, B | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Anderson, C; Craik, CS; Jolly, DJ; Todd, S | 1 |
| Heinrikson, RL; Tomasselli, AG | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Gulick, R | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Jaillon, P; Poirier, JM; Radembino, N; Robidou, P | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE | 1 |
| Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| Tavel, JA | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K | 1 |
| Brouwer, KR; Huang, L; Polli, JW; Serabjit-Singh, C; Woolley, JL; Wring, SA | 1 |
| Levin, J | 1 |
| Prescott, LM | 1 |
| Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Gantke, B; Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
| Pereira, A; Taylor, S | 1 |
| Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 2 |
| Jain, RG; Lenhard, JM | 1 |
| Piliero, PJ | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
| Gamarnik, A; Parkin, N; Resch, W; Swanstrom, R; Ziermann, R | 1 |
| Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB | 1 |
| Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA | 1 |
| Fukumoto, K; Fukushima, K; Gao, W; Inoue, Y; Kageyama, M; Nishimura, A; Shibata, N; Tadano, J; Takada, K; Yamasaki, D; Yoshikawa, Y | 1 |
| DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G | 1 |
| Hruz, PW; Koster, JC; Nichols, CG; Qiu, H; Remedi, MS | 1 |
| Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Sterlingot, H | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Klein, HH; Meier, M; Schütt, M; Zhou, J | 1 |
| Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T | 1 |
| Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q | 1 |
| Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Bihani, SC; Das, A; Ferrer, JL; Hosur, MV; Prashar, V | 1 |
| Annaert, P; Augustijns, P; Camus, S; Ye, ZW | 1 |
| Baki, L; Baumgarten, CM; Deng, W; Yin, J; Zhou, H | 1 |
| Adnot, S; Amsellem, V; Brégeon, J; Dubois-Randé, JL; Gary-Bobo, G; Houssaini, A; Marcos, E; Pacaud, P; Perrin, A; Rideau, D; Savale, L; Sitbon, O | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Cieplak, P; Deng, NJ; Lai, L; Zhang, P | 1 |
| Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ | 1 |
| Liu, L; Unadkat, JD | 1 |
| Haugaard, SB | 1 |
| Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL | 1 |
| Wang, RG; Zhang, HX; Zheng, QC | 1 |
15 review(s) available for nelfinavir and amprenavir
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Resistance to human immunodeficiency virus type 1 protease inhibitors.
Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
HIV protease as a target for retrovirus vector-mediated gene therapy.
Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection | 2000 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Alteration in pancreatic islet function in human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Nelfinavir; Ritonavir; Sulfonamides | 2014 |
6 trial(s) available for nelfinavir and amprenavir
| Article | Year |
|---|---|
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Topics: Adult; Biological Availability; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Saquinavir; Sulfonamides | 2002 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
96 other study(ies) available for nelfinavir and amprenavir
| Article | Year |
|---|---|
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Topics: Anti-HIV Agents; Drug Design; HIV Protease Inhibitors; Thiazoles | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Structure; Mutation; Rats; Structure-Activity Relationship; Sulfonamides | 2004 |
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication | 2004 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids | 2005 |
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication | 2005 |
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Topics: Drug Design; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Conformation; Pyrimidinones; Quantitative Structure-Activity Relationship | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Topics: Amino Acid Sequence; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship | 2008 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Topics: Aspartic Acid Endopeptidases; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Indinavir; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids | 1996 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Inhibition of adipocyte differentiation by HIV protease inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Carbamates; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Furans; Gene Expression; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Mice; Myelin P2 Protein; Nelfinavir; Neoplasm Proteins; Nerve Tissue Proteins; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Ritonavir; Stem Cells; Sulfonamides; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 1999 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
When to switch and what to switch to: strategic use of antiretroviral therapy.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Practice Guidelines as Topic; Pyrimidinones; Retroviridae; Retroviridae Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors; Treatment Failure; Viral Load | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
Topics: Carbamates; Chromatography, Liquid; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides | 2000 |
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea | 2000 |
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Furans; HIV Protease Inhibitors; Humans; Intestinal Mucosa; Intestines; Liver; Male; Nelfinavir; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Sulfonamides; Tumor Cells, Cultured | 2001 |
Phase III trials for new PI.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1998 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumococcal Infections; Sulfonamides; Vaccination; Viral Load | 1998 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides | 2001 |
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Furans; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides; Time Factors | 2002 |
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides | 2002 |
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab
Topics: Carbamates; Cell Line; Coculture Techniques; Drug Resistance, Viral; Furans; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Protein Precursors; Sulfonamides; Virus Replication | 2002 |
Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Topics: Animals; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Half-Life; HIV Protease Inhibitors; Indinavir; Intestinal Mucosa; Liver; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2002 |
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Topics: Animals; Carbamates; Drug Interactions; Furans; Indinavir; Infusions, Intravenous; Intestinal Absorption; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2003 |
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Topics: Animals; Carbamates; Cells, Cultured; Furans; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nelfinavir; Ritonavir; Sulfonamides | 2003 |
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Western; Carbamates; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Lamin Type A; Mice; Microscopy, Confocal; Nelfinavir; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription Factors | 2003 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors | 2004 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment | 2005 |
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System | 2005 |
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Topics: Asparagine; Aspartic Acid; Carbamates; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Mutation; Nelfinavir; Sulfonamides | 2009 |
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
Topics: Action Potentials; Animals; Carbamates; Chloride Channels; Furans; HIV Integrase Inhibitors; HIV Protease Inhibitors; Ion Channel Gating; Lopinavir; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Nelfinavir; Pyrimidinones; Pyrrolidinones; Rabbits; Raltegravir Potassium; Reactive Oxygen Species; Ritonavir; Sulfonamides; Time Factors | 2010 |
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.
Topics: Animals; Animals, Newborn; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Pressure; Carbamates; Cell Division; Furans; Hemodynamics; HIV Protease Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Nelfinavir; Pulmonary Artery; Rats; Rats, Wistar; Ritonavir; Sulfonamides | 2010 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.
Topics: Carbamates; Entropy; Furans; HIV Protease; HIV-1; Ligands; Molecular Dynamics Simulation; Nelfinavir; Protease Inhibitors; Protein Binding; Sulfonamides | 2011 |
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides | 2012 |
Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
Topics: Carbamates; Cells, Cultured; Drug Interactions; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Organic Anion Transporters; Ritonavir; Sulfonamides | 2013 |
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi | 2014 |
Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Furans; HIV Protease; Indinavir; Molecular Conformation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Protein Binding; Ritonavir; Sulfonamides | 2020 |